Advanced Biomed (ADVB) Common Equity (2023 - 2026)

Advanced Biomed has reported Common Equity for 4 years, with the latest figure at $9.2 million in Q1 2026.

• Quarterly Common Equity rose 123.01% year-over-year to $9.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.2 million (up 123.01% YoY) and the FY2025 annual result came in at $3.5 million, up 109.08% from the prior year.
• Common Equity fell to $9.2 million in Q1 2026 per ADVB's latest filing, from $9.5 million in the prior quarter.
• Over five years, Common Equity peaked at $9.5 million in Q4 2025 and troughed at -$497797.0 in Q1 2024.
• A 4-year average of $3.2 million and a median of $2.3 million in 2024 frame the typical range for Common Equity.
• The widest YoY moves for Common Equity: up 1431.69% in 2025, down 109.08% in 2025.
• Over 4 years, Common Equity stood at $196841.0 in 2023, then jumped by 214.48% to $619032.0 in 2024, then jumped by 1431.69% to $9.5 million in 2025, then decreased by 2.87% to $9.2 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $9.2 million, $9.5 million, and $3.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.